Comparing Hyperion DeFi (HYPD) & The Competition

Hyperion DeFi (NASDAQ:HYPD) is one of 422 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Hyperion DeFi to similar companies based on the strength of its risk, analyst recommendations, institutional ownership, dividends, earnings, profitability and valuation.

Risk and Volatility

Hyperion DeFi has a beta of 2.42, suggesting that its share price is 142% more volatile than the S&P 500. Comparatively, Hyperion DeFi’s rivals have a beta of 1.37, suggesting that their average share price is 37% more volatile than the S&P 500.

Insider and Institutional Ownership

25.8% of Hyperion DeFi shares are owned by institutional investors. Comparatively, 29.4% of shares of all “Biotechnology” companies are owned by institutional investors. 10.9% of Hyperion DeFi shares are owned by company insiders. Comparatively, 22.4% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Hyperion DeFi and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Hyperion DeFi	$60,000.00	-$49.82 million	-0.11
Hyperion DeFi Competitors	$155.98 million	-$11.44 million	-59.00

Hyperion DeFi’s rivals have higher revenue and earnings than Hyperion DeFi. Hyperion DeFi is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Hyperion DeFi and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	-62,238.41%	N/A	-316.90%
Hyperion DeFi Competitors	-14,816.17%	40.80%	-32.07%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Hyperion DeFi and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	0	4	0	0	2.00
Hyperion DeFi Competitors	859	2224	4769	58	2.51

Hyperion DeFi currently has a consensus price target of $2.00, suggesting a potential downside of 68.20%. As a group, “Biotechnology” companies have a potential upside of 33.25%. Given Hyperion DeFi’s rivals stronger consensus rating and higher probable upside, analysts plainly believe Hyperion DeFi has less favorable growth aspects than its rivals.

Summary

Hyperion DeFi rivals beat Hyperion DeFi on 11 of the 13 factors compared.

Hyperion DeFi Company Profile

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.